Sinovac’s R & D focuses on two aspects:

Original Vaccines for New Infectious Diseases such as SARS and Avian Influenza

Sinovac has a highly organized and competent R&D department. It uses creative methods and cutting edge technology, combined with government support to develop and market modern, world class vaccines. The results of Sinovac’s R&D is so dramatic that it leads the world SARS vaccine research and has partnered with China’s Center for Disease Control to develop an avian flu vaccine. Through Sinovac’s R & D successes, the Company will gain international recognition along side the industries’ international giants.


Technological Renovation of Traditional Vaccines
Japanese Encephalitis

Developing nations and international health organizations have used technologically old, inexpensive vaccines for mass inoculations for many years. However, with a growing global economy, the market for vaccines that prevent endemic viruses like Japanese Encephalitis have been neglected. SINOVAC is developing inexpensive, modern vaccines that target this emerging market and that can compete with older technology vaccines for large-scale government and international health organization vaccination programs.